市場調查報告書
商品編碼
1150171
心臟安全服務全球市場規模、份額和行業趨勢分析報告:按類型、最終用戶、服務類型和地區劃分的展望和預測,2022-2028 年Global Cardiac Safety Services Market Size, Share & Industry Trends Analysis Report By Type, By End User, By Type of Service, By Regional Outlook and Forecast, 2022 - 2028 |
到 2028 年,全球心臟安全服務市場規模預計將達到 11 億美元,預測期內的複合年增長率為 11.1%。
心血管系統的所有組成部分,包括心臟、血管和血液成分,都受到心血管安全責任的影響,包括心血管和非心血管藥物。心血管副作用可以是功能性或結構性的(例如,組織病理學),並且可以在急性或慢性治療後發生。
在當今世界,公眾監督日益嚴格,經營成本不斷上升,監管資源有限,因此比以往任何時候都更需要有效和安全的藥物開發。心血管疾病 (CVD) 每年有 1790 萬人死亡,是全世界最常見的死亡原因。腦血管病、冠心病、風濕性心髒病都屬於稱為CVD的心臟和血管疾病範疇。
COVID-19 影響分析
這促使製藥和健康保險行業做出必要的改變,以更好地為他們服務。此外,醫學的進步需要許多專門研究心臟健康的研究機構和組織的參與。與冠狀病毒相關的災難已導致許多患有既往疾病的患者死亡,並影響了心臟安全服務。 COVID-19的蓬勃市場發展對整個心臟安全服務市場產生了積極影響。
市場增長因素
生物仿製藥和生物製品研究的增加
許多公司都在大力投資生物製劑和生物仿製藥的研發。在探索階段,多□、蛋白質和單克隆抗體等生物製劑佔治療候選藥物的一半以上。製藥和生物製藥公司正在大力投資研發新的生物製品,以開發或在研產品。此外,生物仿製藥是專利生物製劑的仿製藥,不受嚴格監管,因此價格較低。
Ech 露背服務在普通人群中的流行度很高
心電圖動態心電圖的流行很大程度上是由於老年人口的增加和心血管疾病發病率的增加。根據 Health System Tracker 發布的數據,心髒病是美國的主要死因。由於這些原因,需要能夠即時檢測心跳並時刻監控心跳的設備。在過去幾年中,醫療保健系統已採用心電圖監測設備來檢查異常心臟活動。
市場製約因素
臨床試驗缺乏合格人員
製藥、生物技術和醫療器械研發外包行業瞬息萬變。需要高技能的專業人員提供高質量的服務,遵守可接受的實驗室程序,並跟上醫療器械和藥物研發技術和方法的進步。 CRO 與生物技術、製藥和醫療器械公司以及研究和學術機構競爭訓練有素、經驗豐富的科學家,因此難以吸引和留住高技能人才。
按類型劃分的前景
心臟安全服務市場按類型分為集成式和獨立式。綜合細分市場在 2021 年的收入份額最高的心臟安全服務市場佔據主導地位。這些最先進的核心實驗室服務提供全方位的心臟安全服務,包括成像、TQT 和 QT 曲線測試。為了支持對心率和節律的實時評估,我們還查看脫靶心血管債務並在持照護士的監督下進行現場多通道遙測。
按服務類型劃分的前景
心臟安全服務市場按服務類型分為 ECG/Holter 測量、血壓測量、心血管成像、QT 測試和其他服務。 ECG/Holter 測量部分將在 2021 年見證心臟安全服務市場中最大的收入份額。智能手錶和其他個人電子產品提供心電圖監測。一種稱為 Holter 監視器的小型便攜式設備用於捕捉您的心跳。它用於識別和評估異常心跳(心律失常)的可能性。
最終用戶視角
心臟安全服務市場根據最終用戶細分為製藥/生物製藥公司和合同研究組織。合同研究機構部門在 2021 年提高了心臟安全服務市場的可觀收入份額。臨床試驗由合同研究組織 (CRO) 為製藥、醫療器械和生物技術公司以及學術機構、政府機構和基金會進行。
區域展望
按地區劃分,對北美、歐洲、亞太地區和拉美地區的心臟安全裝置進行了分析。北美地區將在 2021 年佔據心臟安全服務市場的最高收入份額。這是由於該地區的臨床研究數量不斷增加以及對心臟安全服務的需求不斷增加。越來越多的心血管疾病 (CVD) 和冠心病 (CHD) 患者正在加速該地區的藥物開發和研究。
收購是市場進入者採取的主要策略。根據 Cardinal 矩陣中的分析,Pharmaceutical Product Development, Inc. 是心臟安全服務市場的領先先驅。 Koninklijke Philips N.V.、Laboratory Corporation of America Holdings 和 IQVIA Holdings, Inc. 等公司是心臟安全服務市場的領先創新者。
The Global Cardiac Safety Services Market size is expected to reach $1.1 billion by 2028, rising at a market growth of 11.1% CAGR during the forecast period.
Cardiac safety services assist and design clinical studies & trials and other research necessary for the monitoring of heart safety. These are primarily concerned with tracking the full cardiac safety profile through all clinical trial phases, from Phase I through Phase IV. Guidelines and regulations given by most major and recognized medical authorities of various countries and other regulating agencies are followed while developing cardiac safety clinical trials and studies.
These services include physiologic stress testing, non-invasive cardiac imaging, platelet aggregation, ambulatory blood pressure monitoring, and other services in addition to the QT tests. Due to the grouping of services with an emphasis on end-to-end development, integrated services that provide cardiac safety services are generally favored over standalone services because of the peculiarity of standalone services.
All elements of the cardiovascular system, including the heart, blood vessels, and blood constituents, are affected by cardiovascular safety liabilities, which include both cardiovascular and non-cardiovascular pharmaceuticals. Cardiovascular adverse effects can be functional or structural (such as histopathology) in nature and can happen after acute or chronic treatment.
The need for effective yet secure drug development is more critical than ever in a time of growing public scrutiny, rising business expenses, and limited resources at regulatory agencies. With 17.9 million deaths per year, cardiovascular diseases (CVDs) are the most common cause of death worldwide. Cerebrovascular disease, coronary heart disease, rheumatic heart disease, and other illnesses are among the category of heart and blood vessel disorders known as CVDs.
COVID-19 Impact Analysis
This prompted the pharmaceutical and health insurance industries to make the necessary changes to their offerings in order to include better provisions and facilities. In order to progress the evolution of medicine, this compelled the engagement of numerous research institutions and organizations dedicated to heart health. Coronavirus-related catastrophes caused a significant number of patients with pre-existing unfavorable disorders to succumb to them, which had an effect on cardiac safety services. As a result of COVID-19's vigorous promotion of its development, the market for cardiac safety services was positively affected overall.
Market Growth Factors
Increase In Research For Biosimilars And Biologics
Numerous businesses are making significant investments in the creation of biologics and biosimilar compounds. In the discovery stage, biologics such peptides, proteins, and monoclonal antibodies make up more than half of the therapeutic candidates. Pharmaceutical and biopharmaceutical businesses are heavily putting money into their research and development as novel biologics are being developed or are in the pipeline. Biosimilars are also less expensive because, being generic versions of patented biologic medications, they are not subject to the same strict regulatory standards.
High Prevalence Of Ech Holter Service Among The General Population
The rise in the number of elderly people and the increasing incidence of cardiovascular disorders are mostly to blame for the ECG Holter's expansion. According to data released by Health System Tracker, heart disease is the top cause of mortality in the United States. These reasons make immediate heartbeat detection and constant heart rate monitoring equipment necessary. In the past few years, the healthcare system has employed ECG monitoring devices to look for any abnormalities in cardiac activity.
Market Restraining Factors
Lack Of Qualified Personnel For Clinical Trials
The R&D outsourcing industry for pharmaceuticals, biotechnology, and medical devices is always changing. To deliver high-quality services, adhere to acceptable laboratory procedures, and keep up with the ongoing developments in medical device and pharmaceutical R&D technologies and techniques, highly skilled experts are needed. As they compete for trained and experienced scientists with biotechnology, pharmaceutical, and medical device businesses as well as research and academic organizations, CROs confront difficulties in attracting and keeping highly skilled personnel.
Type Outlook
Based on type, the cardiac safety services market is bifurcated into integrated and standalone. The integrated segment dominated the cardiac safety services market with the highest revenue share in 2021. These cutting-edge core lab services provide a full range of cardiac safety services, including imaging, TQT, and profile QT tests. In order to help with the real-time evaluation of heart rate and rhythm, they also keep an eye on off-target cardiovascular liabilities and conduct onsite multichannel telemetry under the supervision of licensed nurses.
Type of Service Outlook
On the basis of type of service, the cardiac safety services market is divided into ECG/Holter measurement, blood pressure measurement, cardiovascular imaging, thorough QT studies, and other services. The ECG/Holter measurement segment witnessed the largest revenue share in the cardiac safety services market in 2021. Smartwatches and other personal electronics provide electrocardiogram monitoring. A small, portable gadget called a Holter monitor is used to capture heartbeats. It is employed to identify and evaluate the likelihood of aberrant heartbeats (arrhythmias).
End User Outlook
Based on end user, the cardiac safety services market is categorized into pharmaceutical & biopharmaceutical companies and contract research organizations. The contract research organizations segment procured a substantial revenue share in the cardiac safety services market in 2021. Clinical trials are carried out by Contract Research Organizations (CROs) for the pharmaceutical, medical device, and biotechnology businesses as well as for academic institutions, governmental agencies, and foundations.
Regional Outlook
On the basis of region, the cardiac safety devices is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region acquired the highest revenue share in the cardiac safety services market in 2021. This is due to the region's growing number of clinical studies, which are fueling demands for cardiac safety services. The rising number of people suffering from cardiovascular diseases (CVD) and coronary heart disease (CHD) have accelerated the drug development and research studies in the region.
The major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix; Pharmaceutical Product Development, Inc. is the major forerunner in the Cardiac Safety Services Market. Companies such as Koninklijke Philips N.V., Laboratory Corporation of America Holdings, IQVIA Holdings, Inc. are some of the key innovators in Cardiac Safety Services Market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Koninklijke Philips N.V., Clario, IQVIA Holdings, Inc., Laboratory Corporation of America Holdings, Pharmaceutical Product Development, Inc., SGS S.A., Banook Group, Biotrial Research SAS, Certara, Inc., and Celerion.
Strategies deployed in Cardiac Safety Services Market
Aug-2022: Labcorp acquired RWJBarnabas Health, a network of independent healthcare providers in New Jersey. Through this acquisition, Labcorp planned to offer expanded health plan coverage, enhanced service to rural markets, and the potential for reduced out-of-pocket lab costs for patients.
Jun-2022: The Banook Group expanded its geographical footprint by opening its first US office in Boston, Massachusetts. Through this expansion, Banook aimed to reduce the constraints of time zones and to provide enhanced technical and logistics support to its customers as about 40% of Banook's customers are based in this region. The expansion also allowed the company to offer local support to its 70 current US customers and to grow in the North American market.
Apr-2022: Royal Philips, partnered with Prisma Health, South Carolina's largest non-profit healthcare system. Through this partnership, the companies agreed to help the health system achieve enterprise interoperability, standardize patient monitoring, and drive innovation in enterprise imaging solutions to enhance patient care and improve clinical performance.
Mar-2022: IQVIA unveiled OCE+, the first of several new advancements to its leading life science customer engagement platform. OCE+ adds IQVIA's Next Best recommendation engine to its Orchestrated Customer Engagement (OCE) platform, providing enhanced HCP experiences, improved productivity, and increased ROI. The product uses IQVIA's industry-leading data and advanced analytics to deliver AI-driven recommendations directly into the daily workflows of life sciences commercial teams.
Jan-2022: Clario partnered with ActiGraph, a pioneer and leading provider of activity-sensing wearable technology. From this partnership, Clario expanded its evidence generation platform and portfolio of decentralization technologies and offered ActiGraph technologies to its customers in addition to its suite of eCOA, Precision Motion, Cardiac Safety, Respiratory, Medical Imaging, and Trial Enablement solutions. The partnership also helped clinical trial sites and sponsors to drive up efficiency and accuracy while increasing convenience for study participants.
Dec-2021: Labcorp took over Personal Genome Diagnostics (PGDx), a provider of comprehensive liquid biopsy and tissue-based genomic products and services. From this acquisition, Labcorp aimed to strengthen its next-generation sequencing-based genomic profiling capabilities and accelerate the existing liquid biopsy capabilities.
Nov-2021: Royal Philips acquired Cardiologs, a French medical technology firm. From this acquisition, Royal Philips aimed at expanding its cardiac monitoring and diagnostics portfolio with innovative software technology, electrocardiogram (ECG) analysis, and reporting services.
Sep-2021: The Banook Group acquired Nabios, biotech with strong expertise in cardiac safety assessments in clinical trials of drugs intended for human health. Through this acquisition, the company advanced its steps towards becoming the leader in the cardiac safety market by offering a strong European alternative to those companies operating from North America or India. This acquisition also granted Banook's customers access to new and more competitive services.
Sep-2021: IQVIA collaborated with HealthCore, a leading real-world research organization in the United States. Under the collaboration, the companies focused on advancing real-world evidence (RWE) studies with increased quality and efficiency. The innovative research collaboration focused specifically on real-world studies such as external comparators, pragmatic trials, and enriched studies.
Mar-2021: Certara took over AUTHOR!, a provider of medical writing and statistical analysis of clinical trial data to global pharmaceutical and biotechnology companies. Through this acquisition, Certara enhanced the existing regulatory and biostatistical expertise and helped to fuel the company's strategic expansion in Europe. Additionally, from the acquisition, Certara leveraged AUTHOR!'s seasoned team to provide technology-enabled capabilities to its customers and thus help global clients expertly navigate and accelerate the drug development and regulatory approval process.
Feb-2021: Royal Philips took over BioTelemetry, a leading U.S.-based provider of remote cardiac diagnostics and monitoring. Through this acquisition, Royal Philips expanded its cardiac care portfolio, and its strategy to transform the delivery of care along the health continuum with integrated solutions.
Feb-2021: Philips formed a partnership with SAZ hospital network, a Dutch Hospital network comprising 28 hospitals. Under this partnership, Philips offered advanced patient monitoring and population health management solutions to the SAZ network hospitals. In addition, Philips solutions enabled SAZ to enhance monitoring, observation, and self-management of patients across the care journey, both inside and outside the hospitals.
Mar-2018: Certara introduced Quantitative Systems Pharmacology (QSP) Immuno-oncology Simulator Consortium. The product combines computational modeling and experimental methods to examine the mechanistic relationships between a drug, the biological system, and the disease process. In addition, QSP integrates quantitative drug data with the knowledge of the drug's mechanism of action.
Market Segments covered in the Report:
By Type
By End User
By Type of Service
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures